Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review
| dc.contributor.author | Yavropoulou, M. P. | en |
| dc.contributor.author | Kotsa, K. | en |
| dc.contributor.author | Gotzamani Psarrakou, A. | en |
| dc.contributor.author | Papazisi, A. | en |
| dc.contributor.author | Tranga, T. | en |
| dc.contributor.author | Ventis, S. | en |
| dc.contributor.author | Yovos, J. G. | en |
| dc.date.accessioned | 2015-11-24T16:34:32Z | |
| dc.date.available | 2015-11-24T16:34:32Z | |
| dc.identifier.issn | 1109-3099 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/7814 | |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Biological Markers/blood | en |
| dc.subject | Bone Density Conservation Agents/*adverse effects | en |
| dc.subject | Calcifediol/blood | en |
| dc.subject | Calcium/blood | en |
| dc.subject | Female | en |
| dc.subject | Fibroblast Growth Factors/blood | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxycholecalciferols/*adverse effects | en |
| dc.subject | Hyperparathyroidism, Secondary/blood/chemica | en |
| dc.title | Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review | en |
| heal.abstract | X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form of hypophosphatemic rickets. Standard treatment of XLH patients includes long-term administration of phosphate and calcitriol. Treated patients usually respond well to the conventional therapy and demonstrate amelioration of rachitic symptoms and improved growth. However, long-term administration of phosphate and vitamin D preparations is sometimes complicated with nephrocalcinosis, secondary or tertiary hyperparathyroidism and arterial hypertension. We describe a patient with XLH, caused by a rare missense mutation of the PHEX gene. The patient, while under treatment with alphacalcidol and oral phosphate, developed hypercalciuria, nephrocalcinosis, secondary hyperparathyroidism and arterial hypertension. Cinacalcet was added to the therapeutic regimen and the long-term effects on calciotropic parameters and FGF23 levels are herein reported. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20688626 | - |
| heal.journalName | Hormones (Athens) | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2010 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: